Spinocerebellar Ataxia Clinical Trials 2023

What are the top hospitals conducting spinocerebellar ataxia research?

In the realm of spinocerebellar ataxia, several top hospitals are leading the charge in pioneering clinical trials and advancing our understanding of this complex condition. The University of South Florida in Tampa is making significant strides with four ongoing spinocerebellar ataxia trials and a total of eight trials conducted to date. Since their first recorded trial in 2009, they have been dedicated to unraveling the mysteries surrounding this neurological disorder.

Meanwhile, on the west coast, UCLA in Los Angeles has emerged as a key player in spinocerebellar ataxia research. Although relatively new to these trials with two active studies and only two all-time trials since their inaugural study in 2019, their commitment to exploring innovative approaches is noteworthy.

Moving inland to Chicago, both Northwestern University and the University of Chicago are also deeply invested in unlocking breakthroughs for those affected by spinocerebellar ataxia. Each institution currently has two active clinical trials underway while collectively contributing six completed studies thus far. Northwestern University began its work on this condition back in 2016, whereas the University of Chicago initiated its first trial on spinocerebellar ataxia patients a bit earlier—back in 2010.

Finally, we turn our attention to Michigan's own prestigious medical institution—the University of Michigan located i

Which are the best cities for spinocerebellar ataxia clinical trials?

When it comes to spinocerebellar ataxia clinical trials, several cities stand out as key locations for research and development. Boston, Massachusetts, leads the pack with 5 active trials focusing on troriluzole, SLS-005, and other potential treatments. New york, New York; Los Angeles, California; Tampa, Florida; and Chicago Illinois each have 4 ongoing studies investigating various interventions such as Group 1 inhibitors and BHV-4157. These cities offer individuals living with spinocerebellar ataxia access to cutting-edge clinical trials that hold promise for advancing treatment options and improving outcomes.

Which are the top treatments for spinocerebellar ataxia being explored in clinical trials?

Clinical trials for spinocerebellar ataxia are exploring several promising treatments. Leading the way is SLS-005, currently in one active trial and representing the first listing of its kind in 2022. Troriluzole follows closely behind with one active trial as well, having made its debut on the scene in 2019. BHV-4157 completes the trio, also involved in one active trial and entering the field back in 2017. These innovative therapies offer hope to individuals affected by spinocerebellar ataxia as researchers continue their dedicated efforts towards finding effective treatment options for this condition.

What are the most recent clinical trials for spinocerebellar ataxia?

Exciting advancements are being made in the field of spinocerebellar ataxia, with recent clinical trials offering potential new treatments. SLS-005 and troriluzole have shown promise in their respective phases for addressing this condition. Additionally, BHV-4157 has reached phase 3 trials, indicating progress towards a future treatment option. These studies mark significant milestones in the pursuit of effective therapies for spinocerebellar ataxia, bringing hope to individuals affected by this neurological disorder.

What spinocerebellar ataxia clinical trials were recently completed?

Recently completed clinical trials for spinocerebellar ataxia, a progressive neurological disorder, have brought new insights and potential treatments to the forefront. Prominent among these trials is the study of NRX-101 by NeuroRx Inc., which concluded in April 2021. Another notable trial involved the investigation of KPS-0373 by KaPe Therapeutics and was finalized in March 2021. These recent advancements highlight the commitment of researchers to advance our understanding and treatment options for spinocerebellar ataxia, offering hope for patients grappling with this debilitating condition.